KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Non-Current Assets (2017 - 2025)

Aquestive Therapeutics has reported Non-Current Assets over the past 9 years, most recently at $11.2 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $11.2 million for Q4 2025, down 15.51% from a year ago — trailing twelve months through Dec 2025 was $48.1 million (down 14.64% YoY), and the annual figure for FY2025 was $11.2 million, down 15.51%.
  • Non-Current Assets for Q4 2025 was $11.2 million at Aquestive Therapeutics, down from $11.9 million in the prior quarter.
  • Over the last five years, Non-Current Assets for AQST hit a ceiling of $17.6 million in Q1 2023 and a floor of $11.2 million in Q4 2025.
  • Median Non-Current Assets over the past 5 years was $14.3 million (2021), compared with a mean of $14.7 million.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 34.37% in 2023 and later fell 21.21% in 2024.
  • Aquestive Therapeutics' Non-Current Assets stood at $14.7 million in 2021, then increased by 16.61% to $17.2 million in 2022, then dropped by 4.25% to $16.5 million in 2023, then dropped by 19.74% to $13.2 million in 2024, then decreased by 15.51% to $11.2 million in 2025.
  • The last three reported values for Non-Current Assets were $11.2 million (Q4 2025), $11.9 million (Q3 2025), and $12.0 million (Q2 2025) per Business Quant data.